Switching between tumour necrosis factor blockers in spondyloarthritis: A retrospective monocentre study of 222 patients

Clinical and Experimental Rheumatology

Volumn 29, Issue 6, 2011, Pages 1010-1013

  Dadoun, Sabrina ^a,b   Geri, Guillaume ^a,b   Paternotte, Simon ^a,b   Dougados, Maxime ^a,b   Gossec, Laure ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Hopital Cochin ^*  (France)

Author keywords

Effectiveness; Retention; Spondyloarthritis; Switch; Tumour necrosis factor blockers

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ARTHRITIS; ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; SPONDYLOARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UVEITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DISABILITY EVALUATION; DRUG SUBSTITUTION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857596813     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. BRAUN J, DAVIS J, DOUGADOS M, SIEPER J, VAN DER LINDEN S, VAN DER HEIJDE D: First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20. (Pubitemid 43268219)
2. BRAUN J, BRANDT J, LISTING J et al.: Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34. (Pubitemid 40193618)
3. DAVIS JC, VAN der HEIJDE DM, BRAUN J et al.: Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-62. (Pubitemid 41532037)
4. VAN DER HEUDE D, SCHIFF MH, SIEPER J et al.: Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009;68:922-9.
5. INMAN RD, DAVIS JC JR, HEIJDE D et al.: Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase HI trial. Arthritis Rheum 2008;58:3402-12.
6. CARMONA L, GOMEZ-REINO JJ: Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006;8:R72.
7. DUCLOS M, GOSSEC L, RUYSSEN-WITRAND A et al.: Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006;33:2433-8.
8. LLOYD S, BUJKIEWICZ S, WAILOO AJ, SUTTON AJ, SCOTT D: The effectiveness of anti-TNF-{alpha} therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford) 2010;49:2313-21.
9. CANTINI F, NICCOLI L, BENUCCI M et al.: Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 2006;55:812-6. (Pubitemid 44619197)
10. CONTI F, CECCARELLI F, MAROCCHI E et al.: Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007;66:1393-7. (Pubitemid 47492489)
11. COATES LC, CAWKWELL LS, NG NW et al.: Real life experience confirms sustained response to long-term biologies and switching in ankylosing spondylitis. Rheumatology (Oxford) 2008;47:897-900. (Pubitemid 351796381)
12. PRADEEP DJ, KEATACGAFFNEY K, BROOKSBY A, LEEDER J, HARRIS C: Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology (Oxford) 2008;47:1726-7.
13. RUDWALEIT M, VAN DEN BOSCH F, KRON M, KARY S, KUPPER H: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010;12:R117.
14. LIE E, VAN der HEIJDE D, UHLIG T et al.: Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 2011;70:157-63.
15. LORD PA. FARRAGHER TM, LUNT M, WATSON KD, SYMMONS DP, HYRICH KL: Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologies Register. Rheumatology (Oxford) 2010;49:563-70.